According to a new double-blind study, cannabidiol (CBD) showed promising results in treating patients with psychosis.
CBD treats paranoia and hallucinations
One study published in American Journal of Psychiatry presented the results of an experiment in which 88 people with psychosis participated. Part of participants got CBD and others - placebo.
Six weeks later, the group receiving CBD showed a reduction in the incidence of symptoms that accompany psychosis, including delusions, paranoia, and hallucinations.
In addition, patients had improved cognitive performance and increased overall functionality, although these improvements were low.
Dr. Philip McGuire, a lead author of the study and professor of psychiatry and cognitive neuroscience at King's College, London, said cannabidiol might be able to replace some modern neuroleptics for some patients.
“Because CBD (cannabidiol) is a relatively new drug at the moment, clinicians may be just more careful in using it, but instead of using proven neuroleptic drugs. This was one of the reasons why we started the CBD study as a supplement to traditional treatment. However, if CBD tests were positive as monotherapy, it would be useful to use them separately, especially in patients whose neuroleptic was not effective. "
According to some estimates, psychosis is a severe mental disorder affecting one in 13 people during their lifetime. Those, by who psychosis develops, often experience mental and emotional disturbances, paranoia, and a general sense of being disconnected from reality. Psychosis can also be the result of abuse of alcohol or drugs.
CBD Oil - food supplement, full-spectrum of cannabinoids, 970mg CBD oil 10% is a unique dietary ...
CBD Oil - food supplement, full-spectrum of cannabinoids, 475mg CBD, mixed with organic hemp seed oil. ...
Schizophrenia is one of the most common forms of psychosis and affects more than 21 million people worldwide. Bipolar disorder is another common form of psychosis that affects nearly six million adults in the US alone.
The study states that it has previously shown that cannabidiol has antipsychotic properties in studies involving animals and humans. As far as the last study is concerned, the researchers sought to help establish what was actually achieved, the "safety and efficacy" of using CBD to treat patients.
These findings may surprise those who have long read about the relationship between hemp and the development of schizophrenia. This discrepancy is related to the difference between CBD and THC.
One of the main differences between these two cannabinoids is that THC causes psychoactive effects, whereas cannabidiol does not. In other words, consuming CBD alone does not make users feel "high".
On the other hand, THC is responsible for the appearance of the smoker's anxiety and changes in mental states that lead to psychosis. In many ways, CBD and THC cause opposite effects among users.
But the combination of CBD and THC (in small amounts) makes the effect against psychosis more effective.
On the eve of the New Year, the United Nations Department of Health and the World Health Organization have published a joint report stating that CBD should not be considered a prohibited drug because it has "therapeutic value" and no potential for abuse.